|  |
| --- |
| Using Trikafta in adult liver transplant recipients and CFLD |
| Ruth Semprini1,2, Amanda Chen1, Brendan Ah Chan1, Andrew Davies1, Megan Powell1, Rob Hackett1 |
| *1Capital, Coast and Hutt Valley, Te Whatu Ora Health New Zealand*  *2Medical Research Institute of New Zealand* |
| **Introduction/Aim:**  The use of elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis (CF) has resulted in improved quality of life, body mass index (BMI) and lung function tests. It is not recommended in those with liver transplants or CF-related liver disease (CFLD) due to well documented derangement of liver function tests (LFTs) and potential interactions with immunosuppressive agents. We report our experience with the use of ETI in a single centre in those with liver transplants and CFLD.  **Methods:**  A retrospective case series including patients started on ETI with liver transplantation or in those with CFLD.  **Results:**  Four patients were identified. Two patients had liver transplants (both male). Two patients had CFLD with cirrhosis and portal hypertension (both female), classed at Child Pugh B8 and A5. Median age across all four patients was 25years (range 20 to 48years), median FEV1 prior to starting ETI was 2.81L (range 1.37L to 3.01L). The time from transplant for the two recipients was 12years and 3years. Three patients were commenced on full dose ETI therapy. One patient, with severe cirrhosis and portal hypertension (Child Pugh B8), was started on twice weekly dosing ETI and increased to alternate day dosing with stable LFTs as their ongoing dose. ETI was discontinued in one patient 3yr post-liver transplant who had deranged LFTs five months after starting ETI. Liver biopsy confirmed drug induced liver injury and re-challenge was not successful. Monitoring of LFTs for all patients was initially performed weekly for one month, then fortnightly for a month then monthly from then on. Tacrolimus dose was reduced in both transplant recipients in anticipation of ETI commencement. All patients demonstrated improvement in quality of life, BMI and lung function after starting ETI.  **Conclusion:**  Initiation of ETI in patients with CF with liver transplants or with CF related cirrhosis is safe with close monitoring.  **Grant Support:** None to declare |